Unlocking Opportunities in the Respiratory Biologics Market: 2025-2034 Forecast Report

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Respiratory Biologics Industry Market Size Be by 2025?
In recent times, there has been a remarkable growth in the size of the respiratory biologics market. The market value is projected to increase from $6.38 billion in 2024 to $7.41 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 16.1%. Factors driving this historical growth include the mounting incidence of respiratory diseases, the surge in personalized medicine adoption, worldwide growth in healthcare spending, improved awareness and diagnosis of respiratory conditions, and a larger aging population dealing with respiratory disorders.

What's the Long-Term Growth Forecast for the Respiratory Biologics Market Size Through 2029?
The market for respiratory biologics is projected to experience a significant surge in the coming years, with estimations pointing to a value of $13.51 billion in 2029 and a compound annual growth rate (CAGR) of 16.2%. Several factors such as the increasing occurrence of asthma and COPD, heightened adoption rates of biologic therapies, escalated R&D expenditure and a rising demand for non-invasive medication delivery methods, coupled with the widening range of reimbursement policies are driving this growth. The projected period will also see major trends like the adoption of monoclonal antibodies for treating respiratory conditions, advancements in biologic drug preparation and delivery techniques, regulatory authorizations, strategic partnerships and acquisitions among key market participants, and the inclusion of artificial intelligence in the discovery and development of drugs.

View the full report here:
https://www.thebusinessresearchcompany.com/report/respiratory-biologics-global-market-report

What Are the Key Growth Drivers Fueling the Respiratory Biologics Market Expansion?
The escalation of air contamination is predicted to drive the expansion of the respiratory biologics industry. Air pollution denotes the existence of detrimental elements like gases, particulate matter, and biological molecules in the Earth's atmosphere, posing serious threats to both human well-being and the ecosystem. This pollution level is surging due to increased industrialization and urbanization, causing escalated release of pollutants from industrial units, automobiles, and construction works. Respiratory biologics are instrumental in fighting the health hazards of air pollution through special treatments that decrease inflammation and optimize lung activities in people exposed to air pollutants. For example, in January 2025, the United States Environment Protection Agency, a government entity based in the US, reported over 66 million tons of pollutants were emitted into the atmosphere in 2023. Additionally, in September 2022, the United Nations Environment Programme, an environmental regulatory body located in Kenya, reported that annually air pollution causes 7 million premature deaths, and 99% of the global population inhales unhealthy air. As such, the growth of air pollution is fueling the expansion of the respiratory biologics industry.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=23497&type=smp

Which Fast-Growing Trends Are Poised to Disrupt the Respiratory Biologics Market?
The key players in the respiratory biologics market are concentrating their efforts on the creation of advanced biologic treatments, such as targeted immune therapies for chronic respiratory conditions. These therapies are designed to guide the body's defense system in reducing inflammation and enhancing lung function in prolonged lung diseases. A pertinent example of this advancement is the announcement by Sanofi S.A, a pharmaceutical firm based in France, in September 2024. They stated that the US Food and Drug Administration (FDA) has given approval to Dupixent (dupilumab). This drug serves as additional maintenance therapy for adults experiencing inadequately managed chronic obstructive pulmonary disease (COPD) with an eosinophilic phenotype. This approval symbolized a significant breakthrough as Dupixent emerged as the pioneering biologic medication authorized in the US for treating this particular set of COPD patients.

How Is the Respiratory Biologics Market Segmented?
The respiratory biologics market covered in this report is segmented -

1) By Disease Indication: Asthma, Chronic Rhinosinasitis, Hypereosinophilic Syndrome
2) By Route Of Administration: Intravenous, Subcuteneous
3) By Sales Channel: Hospitals, Specialty Clinics, Retail Pharmacies, Mail Order Pharmacies

Subsegments:
1) By Asthma: Severe Eosinophilic Asthma, Allergic Asthma, Non-Allergic Asthma
2) By Type: Chronic Rhinosinusitis: Chronic Rhinosinusitis with Nasal Polyps, Chronic Rhinosinusitis without Nasal Polyps
3) By Hypereosinophilic Syndrome (HES): Idiopathic HES, Lymphocytic Variant HES, Myeloproliferative HES

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=23497&type=smp

Which Companies Are Leading the Charge in Respiratory Biologics Market Innovation?
Major companies operating in the respiratory biologics market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., AstraZeneca plc, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Viatris Inc., Regeneron Pharmaceuticals Inc., Boehringer Ingelheim International GmbH, Biogen Inc., Vertex Pharmaceuticals Incorporated, Swedish Orphan Biovitrum AB, Glenmark Pharmaceuticals Ltd., Zymeworks Inc., Kiniksa Pharmaceuticals Ltd., Pieris Pharmaceuticals Inc.

Which Regions Are Leading the Global Respiratory Biologics Market in Revenue?
North America was the largest region in the respiratory biologics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the respiratory biologics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=23497

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.